ClinicalTrials.gg
CompletedNCT03086681ECWHCCFLACCUpdated Jul 29, 2025

Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma

A Phase 2 interventional study of Endostar and DDP in Cervical Carcinoma, sponsored by Yong Zhang,MD. Completed at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Yong Zhang,MD · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 458 studies in Uterine Cervical Neoplasms with a site in China — 208 open to participants now, 243 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Enrollment
141st of 363
120 · median 89
Started
2017
with 14 others
Phase 2
139 of 458
73 open now
Registered
57th of 458
by date

Among the 458 studies in Uterine Cervical Neoplasms with a site in China, this one is the 141st largest by enrollment of the 363 interventional ones that give a count, is one of 15 that started in 2017, is one of 139 in phase 2, and was the 57th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

208 of the 458 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

203 more — sign in →

All 208 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 458 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

A total of 120 patients with pathologically confirmed Locally advanced cervical carcinoma were enrolled. Patients were randomly divided into two groups, with 60 patients in each group. One group was treated with Concurrent Chemoradiotherapy combined with Endostar and the other group was treated with Concurrent Chemoradiotherapy. The short term efficacy and the toxic of these treatments were evaluated. The 1-year, 3-year, 5-year overall survival and progression-free survival of patients were analyzed. The investigators data may provide an alternative option for the treatment of Locally advanced cervical carcinoma with high efficacy and low toxicity.

Read the detailed description

This study was a multicenter, randomized controlled clinical trial. A set of unified standards were used, including the clinical research program, inclusion criteria, exclusion criteria, chemoradiotherapy regimen and evaluation criteria. Nine medical centers participated in this study and 120 patients with pathologically confirmed Locally advanced cervical carcinoma were enrolled. These patients were randomly divided into two groups: concurrent chemoradiotherapy combined with Endostar group ( IMRT 45-50Gy, DDP 40mg/m2, per week for 5cycles, Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles) and concurrent chemoradiotherapy group ( IMRT 45-50Gy, DDP 40mg/m2, per week, for 5cycles). After treatment, follow-up was performed every 3 months. The treatment toxicity, local control rate, distant metastasis-free survival, overall survival, progression-free survival were observed and assessed.

03

Conditions studied

  • Cervical Carcinoma

Keywords

  • Cervical carcinoma
  • endostar
  • concurrent chemoradiotherapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients of either gender and aged from 18 to 65 years old.
  • patients with confirmed cervical carcinoma.
  • patients at stage Ib, IIa2, IIb-IVa by FIGO 2009 staging.
  • ≥ 70 (Appendix I)
  • patients with available MRI or CT data of cervical and measurable tumor lesions.
  • patients did not receive any treatment before enrollment.
  • patients with expected survival longer than 6 months.
  • biochemical indexes: WBC > 4,000/mm3, and blood ≥ 100,000 mm3; PT≤UNL; levels of indicators for hepatic and renal function was 1.5 folds of the value.
  • the informed content was obtained from every patient.
  • patients with effective follow-up.

Exclusion criteria

Exclusion Criteria:

  • those with malignant tumors other than cervical carcinoma.
  • those received treatments before enrollmment.
  • lactating women and Pregnant woman.
  • those who were undergoing other drug trials.
  • those with severe complications, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, mental illness and uncontrollable diabetes.
  • those who were treated with tumor targeting drugs.
  • those who could not subject to MRI or CT examination.
  • those who could not meet the requirements of the prescribed dose.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    concurrent chemoradiotherapy + endostar

    4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy

    Drug: Endostar · Drug: DDP

  • Active comparator
    concurrent chemoradiotherapy

    5 cycles of DDP concurrent with radiotherapy

    Drug: DDP

Interventions

06

What researchers measure

Primary outcomes

  1. short-time effect

    3 months after treatment, the subjects go into observation period. MRI/CT will be used for evaluating the carcinoma status.

    Time frame: 3 months

Secondary outcomes

  1. Overall Survival

    OS was calculated from the date of entry into the study to the date of death or the last follow-up visit.

    Time frame: 3 years,5 years

  2. Progression-Free Survival

    PFS was calculated from the date of entry into the study to the date of first physical or radio-graphic evidence of disease progression, death or the last follow-up visit.

    Time frame: 3 years,5 years

07

Study locations

1 site
  • First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
08

References and documents

Publications

  • Wu F, Tang X, Liu W, Luo Z, Huang H, Liu M, Wang H, Liao S, Ma S, Jiang L, Zhang Y. Efficacy of Endostar plus concurrent chemoradiotherapy in locally advanced cervical cancer: a multicenter, phase II randomized trial. Ther Adv Med Oncol. 2025 Oct 3;17:17588359251379397. doi: 10.1177/17588359251379397. eCollection 2025. PubMed 41049580 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Sep 2020, 41 months.

Of 155 non-industry phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's 41 months is close to that.

Counting every sponsor, half of 205 studies reached it within 42 months; a quarter within 29 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2017
First posted
Mar 22, 2017
StartActual
Apr 20, 2017
Primary completionActual
Sep 30, 2020
CompletionActual
Sep 30, 2020
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03086681
Lead sponsor
Yong Zhang,MD
Responsible party
Yong Zhang,MD (MD, First Affiliated Hospital of Guangxi Medical University) — Sponsor-investigator
First posted
Mar 22, 2017
Start date
Apr 20, 2017
Primary completion
Sep 30, 2020
Completion
Sep 30, 2020
Last update
Jul 29, 2025

Study contacts

Yong Zhang, MD
study chair · First Affiliated Hospital of Guangxi Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Endostar protein

Start the discussion